Prognostic factors for women with ovarian germ cell tumors

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

ESMO open·2026

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

ESMO open·2025

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

ESMO open·2025

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.

ESMO open·2025

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

ESMO open·2025

Lung cancer research and treatment: global perspectives and strategic calls to action.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Purple Blossoms.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.

Drug design, development and therapy·2026

Synchronous Low-Grade Appendiceal Mucinous Neoplasm and Neuroendocrine Tumor Presenting as Pseudomyxoma Peritonei: A Case Report.

Cureus·2026

Short communication: Fluorescence preservation of protoporphyrin IX in fresh frozen glioma tissue.

Brain & spine·2026

PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.

Molecular therapy. Nucleic acids·2026

A sequentially activated afterglow probe for AND-gated imaging of alpha-fetoprotein in hepatocellular carcinoma.

Bioactive materials·2026

miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.

Molecular therapy. Nucleic acids·2026

Related Experiment Videos

Prognostic factors for women with ovarian germ cell tumors

Related Concept Videos

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250).

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial.

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Lung cancer research and treatment: global perspectives and strategic calls to action.

Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.

Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.

LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.

Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.

Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial.

Purple Blossoms.

Gradient Boosting Machine-Based Prognostic Model with SurvSHAP Analysis for Predicting Secondary Loss of Response to Infliximab Therapy in Crohn's Disease.

Synchronous Low-Grade Appendiceal Mucinous Neoplasm and Neuroendocrine Tumor Presenting as Pseudomyxoma Peritonei: A Case Report.

Short communication: Fluorescence preservation of protoporphyrin IX in fresh frozen glioma tissue.

PCBP2 facilitates miR-93-5p-mediated repression of GDF11 in HCC cell lines.

A sequentially activated afterglow probe for AND-gated imaging of alpha-fetoprotein in hepatocellular carcinoma.

miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.

Related Experiment Videos

Prognostic factors for women with ovarian germ cell tumors

Related Concept Videos

Related Articles